Zeniquin® Tablets

Expand All
  • Description:

      • Tablets contain marbofloxacin, a fluoroquinolone antibiotic, that is bactericidal against a broad range of Gram-negative and Gram-positive organisms.
      • Used as a second-line antibiotic as indicated by antibiotic sensitivity testing according to principles of prudent use.

        Recommendations for use:

          Treatment of skin and soft tissue infections (superficial pyodermas, wounds and abscesses) associated with marbofloxacin susceptible strains of Staphylococcus intermedius in dogs and Pasteurella multocida in cats, and urinary tract infections (cystitis) associated with marbofloxacin susceptible strains of Escherichia coli and Proteus mirabilis in dogs.

          Pack sizes:

          25 mg – bottles of 100


            • Well absorbed following oral administration. Low protein binding and high lipid solubility means that Zeniquin is widely distributed and penetrates well into the CSF, bronchial secretions and bone, cartilage and prostate. The concentrations reached in respiratory and genitourinary tract secretions and in the prostate are higher than the concentrations reached in plasma.
          • Dosage:

              • Skin and soft tissue infections, dogs and cats. 2.75 mg/kg once daily for five to 14 days. The dosage may be safely increased to 5.5 mg/kg for two to three days beyond the cessation of clinical signs for a maximum of 30 days, should the patient require more intensive antimicrobial therapy.
              • Urinary tract infections, dogs. 2.75 mg/kg once daily for ten to 14 days.


                Store below 30°C (Room temperature).

              • Human Safety

                First Aid Statement

                If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

                Registered label warnings


                DO NOT USE in food producing species of animals.

                FOR USE ONLY in dogs and cats where indicated by antibiotic sensitivity testing according to principles of prudent use.


                This product is contraindicated in immature growing dogs (small and medium breeds up to 8 months of age, large breeds up to 12 months of age, giant breeds up to 18 months of age) and in cats less than 12 months of age. Marbofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect.

                Marbofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones.

                Side Effects

                The following clinical signs were reported during the course of clinical field studies in dogs receiving marbofloxacin at dosages up to 5.5mg/kg daily: decreased or loss of appetite (5.4%), decreased activity (4.4%), and vomiting (2.9%). The following signs were reported in less than one percent of cases: increased thirst, soft stool/diarrhea, behavioural changes, shivering/shaking/tremors, and ataxia. One dog which had a seizure the day before study enrolment experienced a seizure while on marbofloxacin therapy.

                The following clinical signs were reported during clinical field studies in cats receiving dosages up to 5.5mg/kg daily: diarrhea (2.1%) and soft stool (1.4%). Vomiting was reported in less than one percent of cases in cats.


                Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS simulation, which may lead to convulsive seizures. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. Although rare, it is prudent to consider that any fluoroquinolone may have the potential to induce retinal degeneration in cats, especially when used above label dose rates or in animals that may be elderly or suffering from renal or hepatic disease. Safety studies up to 10 times the highest recommended dose have not demonstrated toxic retinopathy in cats treated with marbofloxacin. Safety in breeding or pregnant dogs and cats has not been established.

                            Additional Information

                Compounds (e.g. sucralfate, antacids, and mineral supplements) containing divalent and trivalent cations (e.g. iron, aluminium, calcium, magnesium, and zinc) can interfere with the absorption of quinolones which may result in a decrease in product bioavailability.

              A Better Way To Buy